Table 2.
Maturing OPCs produced chemokines and proinflammatory cytokines. RR-MS opposite to HC CD49d+CD154+ lymphocytes together with maturating OPC created proinflammatory circumstances, which accelerated inflammation in feedback reaction. Cytokines were measured in supernatants of maturating OLs and their co-culture with sorted CD49d+CD154+ lymphocytes by the use of Bio-Plex Pro™ Human Chemokine Assays. Data are presented as means ± SD from independent experiments in RR-MS n = 10 and HC n = 10.
| MO3.13 (2 × 106 cells/mL) | ||||
|---|---|---|---|---|
| Not Polarized | Polarized to OLs | Polarized to OLs + RR-MS CD49d+CD154+ |
Polarized to OLs + HC CD49d+CD154+ |
|
| CCL1 (I-309)) | 3.6 ± 2.21 | 6.8 ± 2.99 | 68.1 ± 18.06 * § | 10.4 ± 4.94 |
| CCL2 (MCP-1) | 391.6 ± 94.32 | 895 ± 209.9† | 977 ± 494.1 | 927 ± 200.3 |
| CCL3 (MIP-1α) | <3.1 | <3.1 | <3.1 | <3.1 |
| CCL7 (MCP-3) | <3.2 | <3.2 | <3.2 | <3.2 |
| CCL8 (MCP-2) | <0.6 | <0.6 | 62 ± 15.9 * § | <0.6 |
| CCL11(Eotaxin) | 64.7 ± 19.57 | 95.6 ± 26.47 | 137.0 ± 31.59 * § | 81.8 ± 21.60 |
| CCL13 (MCP-4) | <9.4 | <9.4 | <9.4 | <9.4 |
| CCL15 (MIP-1 D ) | <3.1 | <3.1 | <3.1 | <3.1 |
| CCL17 (TARC) | <3.4 | <3.4 | <3.4 | <3.4 |
| CCL19 (MIP-3β) | <9.1 | <9.1 | <9.1 | <9.1 |
| CCL20 (MIP-3α) | <8.7 | <8.7 | 99 ± 18.7 * § | <8.7 |
| CCL21 (6Ckine) | 18 ± 4.9 | 29 ± 10.7 | 76.5 ± 18.2 * § | 26 ± 12.94 |
| CCL22 (MDC) | <5.9 | <5.9 | 23 ± 12.1 * § | <5.9 |
| CCL23 (MPIF-1) | <3.5 | <3.5 | <3.5 | <3.5 |
| CCL24(Eotaxin-2) | <1.1 | <1.1 | 71 ± 27.1 * § | 12 ± 11.9* |
| CCL25 (TECK) | 46 ± 18.5 | 69 ± 23.3 | 263 ± 83.3 * § | 79. ± 20.8 |
| CCL26 (Eotaxin-3) | <1.4 | <1.4 | 16.8 ± 2.60 * § | <1.4 |
| CCL27 (CTACK) | 0.4 ± 0.33 | 0.5 ± 0.37 | 29.5 ± 15.19 * § | 1.5 ± 1.25 |
| CX3CL1 (Factalkine) | 57 ± 10.48 | 89 ± 11.8† | 506 ± 46.4 * § | 79 ± 30.9 |
| CXCL12 (SDFα+β) | <5.3 | <5.3 | 264 ± 59.2 * § | <5.3 |
| CXCL1 (Gro-α) | 208.1 ± 79.34 | 347.5 ± 127.78† | 1533.4 ± 301.68 * § | 365.9 ± 195.19 |
| CXCL2 (Gro-β) | 7 ± 3.9 | 21 ± 8.8† | 217.9 ± 185.66 * § | 33 ± 13.5 |
| CXCL5 (ENA-78) | 296. ± 164.8 | 862 ± 227.4† | 10,432 ± 1129.3 * § | 985 ± 395.2 |
| CXCL6 (GCP-2) | 64.8 ± 23.95 | 54.9 ± 27.33 | 329.9 ± 105.99 * § | 64.0 ± 28.58 |
| CXCL8 (IL-8) | 913. ± 209.0 | 3235 ± 998.6† | 16,896 ± 5981.1 * § | 3626 ± 672.1 |
| CXCL9 (MIG) | <4.9 | <4.9 | 69 ± 13.9 * § | <4.9 |
| CXCL10 (IP-10) | <2.6 | <2.6 | <2.6 | <2.6 |
| CXCL11 (I-TAC) | <2.9 | <2.9 | <2.9 | <2.9 |
| CXCL13 (BCA-1) | <0.1 | <0.1 | <0.1 | <0.1 |
| CXCL16 (SCYB16) | 360 ± 178.2 | 383 ± 166.1 | 388 ± 258.7 | 342 ± 187.0 |
| TNF-α | <3.1 | <3.1 | 36.5 ± 12.22 * § | <3.1 |
| IFN-γ | <0.1 | <0.1 | <0.1 | <0.1 |
| IL-1β | <0.3 | <0.3 | 25.8 ± 12.33* § | <0.3 |
| IL-2 | <0.4 | <0.4 | <0.4 | <0.4 |
| IL-4 | <0.4 | <0.4 | <0.4 | <0.4 |
| IL-6 | 3 ± 1.8 | 24 ± 9.8† | 259 ± 13.2 * § | 27 ± 10.2 |
| MIF1 | 1931 ± 822.2 | 2735 ± 767.9† | 3687 ± 872.8 * § | 2708. ± 772.4 |
| IL-10 | <5.1 | <5.1 | <5.1 | <5.1 |
| IL-16 | <13.7 | <13.7 | <13.7 | <13.7 |
| GM-CSF | <1.5 | <1.5 | <1.5 | <1.5 |
†—statistically significant differences between MO3.13 and MO3.13 polarized to OLs; *—statistically significant differences between MO3.13 polarized to OLs and MO3.13 polarized to OLs with CD49d+CD154+ cells; §—statistically significant differences between MO3.13 polarized to OLs with RR-MS CD49d+CD154+ and MO3.13 polarized to OLs with HC CD49d+CD154+ cells. Red font—CXC type chemokines (associated with recruitment of neutrophils and lymphocytes). Blue font—CC type chemokines (associated with recruitment of lymphocytes, monocytes, mast cells and eosinophils). Green font—chemokines which regulate neuronal-glial interactions and development of CNS.